Global Expansion Luye Pharma has an international footprint with R&D centers in China, the U.S. and Europe and a presence in over 80 countries, presenting opportunities to partner on clinical trials, regulatory support, and distribution channels across diverse markets.

Strategic Therapies Focused strength in oncology, CNS and cardiovascular/metabolic areas with a robust pipeline and recent launches such as Zepzelca, indicating potential for collaboration in mid to late-stage assets, generics-to-innovative formulations, and co-promotion in key regions.

Delivery Technologies Expertise in advanced drug delivery platforms (microspheres, liposomes, transdermal systems) creates sales opportunities for specialized contract manufacturing, formulation development partnerships, and tech licensing to improve product differentiation.

Strategic Partnerships Existing collaborations (eg with BeiGene for Goserelin microspheres) and distribution arrangements in markets like Hong Kong, Macao, and Pakistan suggest open avenues for co-commercialization, regional distribution deals, and access programs.

Scale & Compliance Seven manufacturing sites with over 30 production lines and GMP/ISO 27001 systems indicate reliable supply capabilities and quality assurance, aligning with buyer requirements for validated supply, risk management, and audit-ready partnerships.